Novartis Ag (NVS) Short term Debt (2009 - 2026)

Novartis Ag has disclosed Short term Debt across 18 years of filings, most recently posting $9.6 billion for Q2 2026.

• In Q2 2026, Short term Debt rose 15.32% year-over-year to $9.6 billion; the TTM figure through Jun 2026 stood at $9.6 billion (up 15.32% YoY), while the FY2025 annual figure was $5.6 billion, down 31.95% from the prior year.
• Short term Debt came in at $9.6 billion for Q2 2026 at Novartis Ag, up from $7.6 billion in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $9.6 billion in Q2 2026 to a low of $5.5 billion in Q3 2023.
• Average Short term Debt over 5 years is $7.3 billion, with a median of $7.3 billion recorded in 2022.
• Year-over-year, Short term Debt sank 34.13% in 2022 and jumped 33.31% in 2024.
• Over 5 years, Short term Debt stood at $5.9 billion in 2022, then climbed by 4.11% to $6.2 billion in 2023, then jumped by 33.31% to $8.2 billion in 2024, then slumped by 31.95% to $5.6 billion in 2025, then soared by 71.15% to $9.6 billion in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $9.6 billion in Q2 2026, $7.6 billion in Q1 2026, and $5.6 billion in Q4 2025.